INDV Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
343.0M
+8.2%
317.0M
-11.5%
358.0M
+14.0%
314.0M
+4.0%
302.0M
Cost of Revenue
50.0M
+25.0%
40.0M
-40.3%
67.0M
-19.3%
83.0M
+59.6%
52.0M
Gross Profit
293.0M
+5.8%
277.0M
-4.8%
291.0M
+26.0%
231.0M
-7.6%
250.0M
Operating Expenses
134.0M
-4.3%
140.0M
-33.3%
210.0M
+11.7%
188.0M
+5.0%
179.0M
R&D
12.0M
-25.0%
16.0M
-23.8%
21.0M
-36.4%
33.0M
+57.1%
21.0M
SG&A
122.0M
-1.6%
124.0M
-34.4%
189.0M
+21.9%
155.0M
-1.9%
158.0M
Operating Income
159.0M
+16.1%
137.0M
+69.1%
81.0M
+88.4%
43.0M
-39.4%
71.0M
EBITDA
161.0M
+15.8%
139.0M
+63.5%
85.0M
+84.8%
46.0M
-37.0%
73.0M
Net Income
122.0M
+37.1%
89.0M
-12.7%
102.0M
+142.9%
42.0M
+133.3%
18.0M
EPS (Basic)
$1.02
+43.7%
$0.71
-12.3%
$0.81
+138.2%
$0.34
+126.7%
$0.15
EPS (Diluted)
$0.98
+42.0%
$0.69
-10.4%
$0.77
+133.3%
$0.33
+135.7%
$0.14
Shares (Diluted)
124.0M
-3.9%
129.0M
-2.3%
132.0M
+2.3%
129.0M
+2.4%
126.0M
Indivior Pharmaceuticals (INDV) โ€” Financials